Start-Up Spotlight: Fractyl Attacks Insulin Resistance At Its Roots
The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.
You may also be interested in...
Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
Bayer Focuses On Medical Technology For Consumers With Precision Health Unit
German pharma giant says division will help people take control of their own health care with digital products.
Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition covers the two clinical studies of Boston Scientific's Emblem MRI subcutaneous implantable cardioverter defibrillator.